Abstract
Adipose-derived cellular therapies, including stromal vascular fraction (SVF) and adipose-derived stem cells (ASCs), have demonstrated increasing therapeutic potential across regenerative medicine applications. This narrative review examines the current evidence supporting the use of SVF and ASCs in 2 primary clinical contexts: osteoarthritis (OA) and chronic wound healing. SVF, a heterogeneous cell population isolated from lipoaspirated fat via enzymatic or mechanical methods, and ASCs, a more homogeneous culture-expanded mesenchymal cell product, both exert regenerative effects through angiogenic, immunomodulatory, and reparative mechanisms. In OA, both cell types have been shown to significantly reduce pain and improve function, with some studies indicating cartilage regeneration on imaging. While ASCs may offer faster symptom relief due to higher purity and dosing, SVF remains a more accessible, minimally manipulated alternative with comparable long-term outcomes. In wound healing, adipose-derived therapies have been associated with accelerated closure of chronic ulcers through enhanced neovascularization, modulation of the inflammatory microenvironment, and promotion of granulation tissue and re-epithelialization. Across both indications, these therapies have shown a good safety profile, with minimal adverse events reported. The review also addresses regulatory distinctions, standardization challenges, and biologic variability, particularly in SVF preparations. Taken together, the evidence suggests the clinical utility of adipose-derived cellular therapies while highlighting the need for further standardization, long-term safety monitoring, and large-scale randomized trials to confirm efficacy and optimize clinical translation.
Plain Language Summary
This article reviews how cells taken from a person’s own fat tissue—either used directly or after growing them in a lab—are being used to treat conditions like arthritis and chronic wounds. These fat-derived cells, called stromal vascular fraction (SVF) and adipose-derived stem cells (ASC), have shown the ability to reduce inflammation, relieve pain, and even help regenerate damaged tissues like cartilage and skin. The review looked at nearly 20 recent studies and found that some of the studies suggested that in people with knee arthritis, injections of these cells can reduce pain and improve mobility. Some studies showed signs that the treatment may help regrow cartilage. In patients with hard-to-heal wounds, these cells helped close ulcers faster and improved healing quality. Importantly, the treatments were safe, with few reported side effects. Overall, the findings support the growing use of fat-derived cell therapies in regenerative medicine, while also emphasizing the need for more long-term and large-scale studies to confirm their benefits.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
